Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Pongo

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Protein Expression and Purification|April 16, 2018
Antibody engineering to improve manufacturabilitySujeewa D Wijesuriya, Elizabeth Pongo, Milan Tomic, et al.
Mabs|November 5, 2010
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseasesAlexander M Owyang, Hassan Issafras, John Corbin, et al.
Obesity (Silver Spring, Md.)|June 23, 2016
An allosteric antibody to the leptin receptor reduces body weight and reverses the diabetic phenotype in the Lep(ob) /Lep(ob) mouseVinay Bhaskar, Ira D Goldfine, Resi Gerstner, et al.
Mabs|July 21, 2020
COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumorsAnand Panchal, Pui Seto, Russell Wall, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Protein Expression and Purification|April 16, 2018
Antibody engineering to improve manufacturabilitySujeewa D Wijesuriya, Elizabeth Pongo, Milan Tomic, et al.
Mabs|November 5, 2010
XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseasesAlexander M Owyang, Hassan Issafras, John Corbin, et al.
Obesity (Silver Spring, Md.)|June 23, 2016
An allosteric antibody to the leptin receptor reduces body weight and reverses the diabetic phenotype in the Lep(ob) /Lep(ob) mouseVinay Bhaskar, Ira D Goldfine, Resi Gerstner, et al.
Mabs|July 21, 2020
COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumorsAnand Panchal, Pui Seto, Russell Wall, et al.
Pageof 1